Guidde is an AI-powered tool that helps you explain the most complex tasks in seconds with AI-generated documentation. Turn ...

Prompt engineering is a relatively new field of research that refers to the practice of designing, refining, and implementing prompts or instructions that guide the output of large language models ...

run is a universal multi-language runner and smart REPL (Read-Eval-Print Loop) written in Rust. It provides a unified interface for executing code across 25 programming languages without the hassle of ...

Judge says Greenpeace must pay $345 million in pipeline lawsuit, cutting jury amount nearly in half Republican senators strongly rebuke Trump's NATO troop withdrawal Dodgers make lineup changes for ...

I am selling my remaining shares in TARS for 90% gain. I am adding to my position in DERM on the dip back to $7. I am initiating a new position in REPL with 5% portfolio weighting. REPL- FDA's ...

Replimune received FDA acceptance for its RP1 BLA resubmission in advanced melanoma, with a PDUFA date set for April 2026. REPL stock surged nearly 100% on the news, but FDA acceptance only restarts ...

FDA accepted Replimune’s resubmitted Biologics License Application for RP1 combined with Bristol Myers Squibb’s Opdivo to treat advanced melanoma The agency set April 10, 2026 as the decision deadline ...

The biotech received the good news it was hoping for from a top national regulator. This concerned RP1, its advanced melanoma drug. Well before market open, Replimune announced that the U.S. Food and ...

Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...